1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024

  • August 2015
  • 58 pages
  • ID: 2063637
In this report:
While there has been no current estimate discerning the HLA-B## prevalence in the diagnosed AS population, a recent analysis of the National Health and Nutritional Examination Survey (NHANES) 2009-2010 data showed a total prevalence of ##.##% for HLA-B## seropositivity in the adult US population and ##.##% in non-Hispanic white adults (Bakland et al., 2011).

Summary

Table of Contents

Search Inside

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024

Brief

Ankylosing spondylitis - a systemic, chronic, and progressive inflammatory arthritis, is the prototype of a family of related disorders known as seronegative spondyloarthritis and one of the most common rheumatic diseases across the world. AS primarily affects the spine and sacroiliac joints and progresses into severe inflammation that fuses the spine, leading to permanent painful stiffness of the back. AS that occurs before any structural changes in the spine is referred to as non-radiographic axial spondyloarthritis which is the early stage of AS. Some of non-radiographic axial spondyloarthritis progress to AS and some do not.

GlobalData's epidemiological analysis offers a country-specific forecast for the diagnosed prevalent cases of AS in the 7MM during 2014-2024. GlobalData epidemiologists made sure all the country-specific studies report diagnosed prevalent cases of AS, diagnosed prevalent cases of nr-axSpA, and HLA-B27 seropositivity cases in diagnosed AS cases established on medical chart review by a physician or info extracted from national registries. GlobalData epidemiologists provide a forecast for the diagnosed prevalent cases of AS and nr-axSpA using two distinct approaches: 1) forecasting the diagnosed prevalent cases of AS and nr-axSpAusing data obtained from peer reviewed journal articles and 2) forecasting the diagnosed prevalent cases of AS and nr-axSpA by applying a trend established on info obtained from primary research to the diagnosed prevalent cases calculated using the base scenario. The forecast methodology was regular across all the 10MM to allow for a meaningful comparison among them.

The diagnosed prevalent cases of AS in the 7MM in the base scenario increased from 1,045,903 diagnosed prevalent cases in 2014 to 1,067,905 diagnosed prevalent cases in 2024, with an annual increase rate of ~0.2 percent. The forecast in the alternate scenario established on primary research data showed that there will be a substantial increase in the diagnosed prevalent cases of AS in the 7MM from 1,279,010 diagnosed prevalent cases in 2014 to 2,230,825 diagnosed prevalent cases in 2024, at an AGR of ~7.4 percent. The forecast methodology was constant across all the 10MM to allow for a meaningful comparison among them.

Overview

- The Ankylosing Spondylitis EpiCast Report offers an overview of the risk factors, comorbidities, and overall trends for ankylosing spondylitis in the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, Japan (JP)). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of ankylosing spondylitis divided by sex, age (in ten-year increments beginning at 15 years and ending at =65 years), and diagnosed prevalent cases of non-radiographic axial spondyloarthritis, and diagnosed prevalent cases of AS broken down by HLA-B27 seropositivity status in these markets.

- The ankylosing spondylitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The Ankylosing Spondylitis EpiCast series will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall ankylosing spondylitis market.

- Quantify patient populations in the overall ankylosing spondylitis market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for ankylosing spondylitis therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Juvenile Rheumatoid Arthritis Global Clinical Trials Review, H2, 2017

Clinical Research in Juvenile Rheumatoid Arthritis in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Juvenile Rheumatoid Arthritis Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Juvenile Rheumatoid Arthritis Global Clinical Trials Review, H2, 2017" provides an overview ...

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Global Clinical Trials Review, H2, 2017

Clinical Research in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) ...

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Global Clinical Trials Review, H2, 2017

Clinical Research in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Idiopathic Thrombocytopenic Purpura (Immune ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.